Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial-Reference-Cited by-同舟云学术

Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial

Published:2020-06 Issue:6 Volume:82 Page:1524-1526
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Casseres Rachel G.,Prussick Lisa,Zancanaro Pedro,Rothstein Brooke,Joshipura Deep,Saraiya Ami,Turkowski Yana,Au Shiu Chung,Alomran Abdulaziz,Abdat Rana,Abudu Minawaer,Kachuk Courtney,Dumont Nicole,Gottlieb Alice B.,Rosmarin David

Funder

Novartis

AbbVie

Bristol-Myers Squibb

Celgene

Dermira

Incyte

Janssen

Lilly

Merck

Pfizer

Regeneron Pharmaceuticals

XBiotech

UCB

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities;Melnik;Br J Dermatol,2018

2. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents;Matusiak;J Am Acad Dermatol,2017

3. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy;Moran;J Invest Dermatol,2017

4. Two phase 3 trials of adalimumab for hidradenitis suppurativa;Kimball;N Engl J Med,2016

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study;Clinical, Cosmetic and Investigational Dermatology;2024-01

2. Secukinumab in the treatment of hidradenitis suppurativa;Immunotherapy;2023-12

3. Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study;Health Technology Assessment;2023-12

4. Taiwanese Dermatological Association (TDA) consensus recommendations for the definition, classification, diagnosis, and management of hidradenitis suppurativa;Journal of the Formosan Medical Association;2023-12

5. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review;The Journal of Dermatology;2023-11-27